Recently, Brinton has expanded into the paediatric dermatology and respiratory segments.
Brinton Pharmaceuticals Limited has raised $8 million in Series B funding round from India Alternatives Investment Advisors Ltd.
Brinton is focused on dermatology. Recently, it has expanded into the paediatric dermatology and respiratory segments.
Rahulkumar Darda, Chairman & Managing Director, Brinton Pharmaceuticals, said, “We are excited to partner with an investor of the calibre of India Alternatives and strongly believe this association will bring synergies and help us continue our profitable growth journey. This investment will enhance our capabilities in formulations and Research & Development for niche areas of dermatology and cosmetology and support expansion of the company’s footprint within India as well as globally.”
Vijey Christopher J, Director of Brinton Pharmaceuticals, stated, “In a short span of time Brinton has made its presence felt both in dermatology and paediatrics through our innovative high-quality products stemming from world-class R&D units across the globe. We are aiming for a leadership position in our represented product markets and have a strategic road-map to cross several milestones in the coming years.”
Shivani Bhasin Sachdeva, Founder & CEO, India Alternatives, added, “India Alternatives’ investment in Brinton reflects its recognition of the Company’s solid management team, differentiated brands and focus on niche therapeutic segments. The investment in Brinton fits very well with two of our themes of women-oriented consumption and health & wellness. We are excited to partner with Rahul and his team to support them through the next leg of their journey.”